The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Addressing plasmid DNA challenges in large-scale manufacturing of recombinant adeno-associated virus and lentivirus using enzymatically generated dbDNA
Whitepaper
Recent advances in gene therapy have increased the use of recombinant adeno-associated viruses (rAAV) and recombinant lentiviruses (rLV) as gene delivery vectors. However, challenges remain in scaling up their production due to reliance on plasmid DNA (pDNA).
Namely, traditional pDNA manufacturing methods face bottlenecks, including scalability issues and regulatory concerns related to bacterial contaminants and antibiotic resistance genes.
This whitepaper explores the use of doggybone DNA (dbDNATM), a synthetic alternative to pDNA, for producing rAAV and rLV. The results indicate that dbDNA offers a promising solution for overcoming limitations associated with pDNA in large-scale viral vector manufacturing.
